Patient selection for focal therapy of localized prostate cancer

被引:20
作者
Jayram, Gautarn [1 ]
Eggener, Scott E. [1 ]
机构
[1] Univ Chicago, Urol Sect, Chicago, IL 60637 USA
关键词
cryotherapy; focal therapy; high-intensity focused ultrasound; prostate cancer; RADICAL PROSTATECTOMY; PREOPERATIVE PREDICTION; ABLATIVE THERAPY; UNITED-STATES; TUMOR LENGTH; BIOPSY; MANAGEMENT; RATIONALE; PATTERNS; FEATURES;
D O I
10.1097/MOU.0b013e328329eb3c
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Purpose of review Prostate-specific antigen screening has led to a dramatically increased detection of low-grade, small-volume, organ-confined tumors. On the basis of concerns regarding overtreatment of biologically indolent cancers, focal ablative therapy has been introduced as an alternative to radical therapy or active surveillance. Because a critical requirement of focal therapy is appropriate patient selection, we review the pathologic characteristics of localized prostate cancer and methods to identify patients likely to have low-risk disease. Recent findings Up to 33% of patients undergoing radical prostatectomy have unilateral, low-grade, organ-confined tumors on final pathology. Standard diagnostic methods such as ultrasound-guided biopsies may not be adequate to reliably identify these patients. Early data on three-dimensional transperineal and transrectal mapping biopsies have suggested an increased ability to precisely localize and characterize low-grade tumors. The addition of multisequence MRI and spectroscopy to standard diagnostic techniques is under study and may eventually further augment disease characterization. Summary Appropriate selection criteria for focal therapy are evolving, and diagnostic techniques widely vary. Further study of extensive mapping biopsies, imaging techniques, and biomarkers are mandatory to improve the recognition and characterization of patients with biologically indolent lesions and better inform their treatment decision making.
引用
收藏
页码:268 / 273
页数:6
相关论文
共 40 条
[1]
20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[2]
Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach [J].
Andriole, Gerald L. ;
Bullock, Travis L. ;
Belani, Jay S. ;
Traxel, Erica ;
Yan, Yan ;
Bostwick, David G. ;
Humphrey, Peter A. .
UROLOGY, 2007, 70 (6A) :22-26
[3]
[Anonymous], LAB INVEST
[4]
Heterogeneity of gleason grade in multifocal adenocarcinorna of the prostate [J].
Arora, R ;
Koch, MO ;
Eble, JN ;
Ulbright, TM ;
Li, L ;
Cheng, L .
CANCER, 2004, 100 (11) :2362-2366
[5]
BASTIAN PJ, 2004, CANCER, V101, P1923
[6]
Prospective evaluation of men with stage T1c adenocarcinoma of the prostate [J].
Carter, HB ;
Sauvageot, J ;
Walsh, PC ;
Epstein, JI .
JOURNAL OF UROLOGY, 1997, 157 (06) :2206-2209
[7]
The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry [J].
Cooperberg, MR ;
Broering, JM ;
Litwin, MS ;
Lubeck, DP ;
Mehta, SS ;
Henning, JM ;
Carroll, PR .
JOURNAL OF UROLOGY, 2004, 171 (04) :1393-1401
[8]
Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy [J].
Crawford, ED ;
Wilson, SS ;
Torkko, KC ;
Hirano, D ;
Stewart, JS ;
Brammell, C ;
Wilson, RS ;
Kawata, N ;
Sullivan, H ;
Lucia, MS ;
Werahera, PN .
BJU INTERNATIONAL, 2005, 96 (07) :999-1004
[9]
TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort [J].
Darnel, Andrew D. ;
LaFargue, Christopher J. ;
Vollmer, Robin T. ;
Corcos, Jacques ;
Bismar, Tarek A. .
CANCER BIOLOGY & THERAPY, 2009, 8 (02) :125-130
[10]
Djavan B, 1999, Tech Urol, V5, P139